Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Company Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $14.50 to $15.07
• 50-Day Range: $13.42 to $24.69
• 52-Week Range: $3.89 to $36.26
• Volume: 116,186 shs
• Average Volume: 1.44 million shs
• Market Capitalization: $1.32 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.40
• Consensus Rating: Moderate Buy

Olema Pharmaceuticals Stock Analysis - MarketRank™

Olema Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 478th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Olema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Olema Pharmaceuticals has a consensus price target of $44.40, representing about 195.5% upside from its current price of $15.03.

Amount of Analyst Coverage

Olema Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.17) to ($2.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Olema Pharmaceuticals is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Olema Pharmaceuticals is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Olema Pharmaceuticals has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.74% of the float of Olema Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Olema Pharmaceuticals has a short interest ratio ("days to cover") of 14.57, which indicates bearish sentiment.

Change versus previous month

Short interest in Olema Pharmaceuticals has recently increased by 5.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Olema Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Olema Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.73

News Sentiment

Olema Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Olema Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $951,400.00 in company stock.

Percentage Held by Insiders

16.36% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OLMA Stock Analysis - Frequently Asked Questions

How have OLMA shares performed this year?

Olema Pharmaceuticals' stock was trading at $25.00 at the beginning of 2026. Since then, OLMA stock has decreased by 39.9% and is now trading at $15.0270.

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) posted its quarterly earnings results on Monday, March, 16th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01.

When did Olema Pharmaceuticals IPO?

Olema Pharmaceuticals (OLMA) raised $187 million in an IPO on Thursday, November 19th 2020. The company issued 11,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity acted as the underwriters for the IPO.

Who are Olema Pharmaceuticals' major shareholders?

Olema Pharmaceuticals' top institutional investors include Candriam S.C.A. (0.87%), Pictet Asset Management Holding SA (0.25%), Bank of New York Mellon Corp (0.22%) and Fideuram Intesa Sanpaolo Private Banking S.P.A. (0.13%). Insiders that own company stock include Bain Capital Life Sciences Inv, Bvf Partners L P/Il, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen, Shane William Charles Kovacs, Naseem Zojwalla, Shawnte Mitchell and Ian T Clark.
View institutional ownership trends.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Olema Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 3/16/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OLMA
• CIK: 1750284
• Web: www.olema.com
• Phone: 650-243-5555
• Fax: N/A
• Employees: 70
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Olema Pharmaceuticals: $44.40
• High Price Target: $62.00
• Low Price Target: $27.00
• Potential Upside/Downside: +194.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$162.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -42.95%
• Return on Assets: -38.78%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 9.95
• Quick Ratio: 9.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.88 per share
• Price / Book: 2.56

Miscellaneous

• Outstanding Shares: 87,350,000
• Free Float: 72,898,000
• Market Cap: $1.32 billion
• Optionable: Optionable
• Beta: 2.05